TABLE VII -.

Results of the incremental cost-effectiveness analysis

Parameters	Caplacizumab + PEX and immunosuppression	PEX and immunosuppression	Incremental change
Outcomes
Life years (LY)	24.53	21.26	3.27
Quality Adjusted Life Years (QALY)	22.01	18.96	3.06
Direct costs (€)
Caplacizumab	€139,540	€0	€139,540
iTTP Management	€12,553	€15,924	−€3,372
TOTAL direct costs	€152,093	€15,924	€136,169
Incremental cost-effectiveness ratio (ICER)
ICER (Caplacizumab + PEX and immunosuppression vs PEX and immunosuppression) (costs/LY)		€41,653
ICER (Caplacizumab + PEX and immunosuppression vs PEX and immunosuppression) (costs/QALY)		€44,572